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Background: Mineral disorders are associated with adverse renal outcomes in chronic kidney disease (CKD)
patients. Previous studies have associated hypercalcemia and hypocalcemia with mortality; however, the association
between serum calcium and renal outcome is not well-described. Whether adding calcium besides phosphorus or
in the form of calcium-phosphorus (Ca × P) product into the model of survival analysis could improve the prediction
of renal outcomes is not known.
Methods: A prospective cohort of 2144 outpatients with CKD stages 3–4 was evaluated. Cox proportional hazard
analysis was performed according to calcium quartiles.
Results: The mean calcium level was 9.2 ± 0.7 mg/dL. Low serum calcium (<9.0 mg/dL) was associated with
increased risk of requiring renal replacement therapy (RRT) (hazards ratio [HR]:2.12 (95% CI: 1.49–3.02, P <0.05) and
rapid renal function progression (odds ratio [OR]: 1.65 (95% CI: 1.19–2.27, P <0.05) compared with high serum
calcium (>9.8 mg/dL). Adding calcium into the survival model increased the integrated discrimination improvement
by 0.80% (0.12% – 1.91%) while calcium-phosphorus product did not improve risk prediction.
The combination of high serum phosphorus (>4.2 mg/dL) and low serum calcium (<9.1 mg/dL) was associated
with the highest risk of RRT (HR:2.31 (95% CI: 1.45–3.67, P < 0.05).
Conclusion: Low serum calcium is associated with increased risk of RRT and rapid renal function progression in
CKD stage 3–4 patients. The integration of serum calcium and phosphorus, but not calcium-phosphorus product
should be considered in a predictive model of renal outcome.
Keywords: Calcium, Chronic kidney disease, Renal replacement therapyBackground
Bone mineral disorders have been implicated as a risk fac-
tor for mortality and renal replacement therapy (RRT) in
chronic kidney disease (CKD) patients [1-3]. Several ob-
servational studies have shown a significant association
between high phosphorus levels with the progression
of CKD [4,5] and RRT [4,6]. Nevertheless, recent studies
have discovered the relationship between low plasma
25-hydroxyvitamin D (25[OH]D) and 1,25-dihydroxyvitamin* Correspondence: chichi@cc.kmu.edu.tw
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unless otherwise stated.D (1,25[OH]2D) with renal disease progression [7], the ini-
tiation of dialysis [8], and death [7,8]. Although the exact
mechanisms of renal damage are not completely under-
stood, putative mechanisms could be vascular calcification
and arteriosclerosis induced by high serum phosphorus
[9], increased calcium and calcium-phosphorus (Ca × P)
product [10].
The potential role of serum calcium in the prediction
of CKD progression is not well-established. In previous
studies, Young et al. identified that hypercalcemia plays
a critical modifying role in the pathogenesis of ischemic
and toxic renal injury [11], and the association between
hypercalcemia and acute kidney injury was observed in
malignancy, hyperparathyroidism, and sarcoidosis [12].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Lim et al. BMC Nephrology 2014, 15:183 Page 2 of 9
http://www.biomedcentral.com/1471-2369/15/183A study by Schwarz et al. suggested that lower serum
calcium was associated with higher risk of CKD progres-
sion; however, this association was not statistically sig-
nificant [2]. There is no study directly aimed to evaluate
the role of calcium as a risk factor for poor renal out-
come. Moreover, previous case reports have documented
hypocalcemia associated congestive heart failure in both
pediatric and adult population because myocardial con-
tractility may decline in acute and chronic hypocalcemia
[13,14]. The researches regarding relationship between
serum calcium and cardiovascular system in CKD are
limited. Therefore, in this study, we hypothesized that
serum calcium is an independent prognostic marker of
rapid renal function progression, the requirement for
RRT and deterioration in cardiac performance in an ob-
servational cohort of CKD stages 3–4 patients.
Methods
Study population and data collection
A prospective cohort of CKD patients from integrated
CKD care programs in Kaohsiung City was evaluated.
CKD was defined and staged according to the definition
of the Kidney Disease Outcomes Quality Initiative
(KDOQI), and classified using the patients’ baseline esti-
mated glomerular filtration rate (eGFR) [15]. The pa-
tients (n = 3749) were recruited from the nephrology
outpatient departments of 2 hospitals, and were treated
under integrated CKD care programs from November
11, 2002 until May 31, 2009, and followed up until July
31, 2010. The inclusion criteria were being a CKD pa-
tient and not receiving RRT. The exclusion criteria were
acute kidney injury, defined as more than a 50% reduc-
tion in the eGFR within 3 months, patients who were
lost to follow-up in less than 3 months (n = 90),CKD
stage 1, 2 patients due to small sample size (n = 356) and
CKD stage 5 patients. The final study population con-
sisted of 2144 patients with CKD stages 3–4.
At the baseline visit, socio-demographic characteris-
tics, medical history, lifestyle behaviors, and current
medications were recorded. The patients’ medical histor-
ies were confirmed by doctors’ chart-reviews. The pres-
ence of diabetes mellitus (DM) and hypertension was
defined according to clinical diagnosis. Cardiovascular
disease (CVD) was defined as a clinical diagnosis of
heart failure, acute or chronic ischemic heart disease, or
cerebrovascular accident. The patients’ biochemistry mea-
surements were collected on baseline visit, and then every
3 months. The laboratory data from 3 months prior to the
baseline visit to 3 months after the baseline visit were aver-
aged and analyzed. The normal range of serum phosphate
and calcium in our institution are 2.5-4.6 mg/dl and
8.4-10.2 mg/dl respectively. The total calcium was mea-
sured and corrected for serum albumin concentration
using the following formula: corrected calcium (mmol/L) =total calcium (mmol/L) +0.02*(40 g/L - serum albumin in
grams per liter) [16]. Corrected total calcium level is ana-
lyzed in our models. Patients’ calcium levels were divided
into quartiles Ca Q1–Q4 according to cut-off values at
9.0 mg/dL, 9.4 mg/dL, and 9.8 mg/dL.
Echocardiographic assessment
All patients received echocardiography examination an-
nually when they entered CKD stage 5. The echocardio-
graphic examination was performed by experienced
cardiologists who were blind to clinical data using trans-
thoracic echocardiography (Vivid 7, General Electric
Medical Systems, Horten, Norway). Left ventricular mass
index (LVMI) was calculated by dividing left ventricular
mass by body surface area [17].
Ethics statement
The study protocol was approved by the Institutional
Review Board of the Kaohsiung Medical University Hos-
pital (KMUH-IRB-990198). Informed consents were ob-
tained in written form and all clinical investigation was
conducted according to the principles expressed in the
Declaration of Helsinki. The patients gave consent for
the publication of the clinical details.
Renal outcome
RRT was defined as hemodialysis, peritoneal dialysis, or
renal transplantation, or as RRT for more than 3 months.
The timing of administration of RRT was according to
the regulations of the Bureau of the National Health In-
surance of Taiwan for laboratory data, nutritional status,
uremic status, and serum creatinine (>6 mg/dL). Pa-
tients’ charts were reviewed and matched with the data-
base of the Taiwan Society of Nephrology to identify the
cases receiving RRT.
A rapid renal function progression was defined as an
eGFR slope < −5 mL/min/1.73 m2/y. Renal function was
quantified using the eGFR derived from the simplified
Modification of Diet in Renal Disease (MDRD) study
equation. The average eGFR slope (mL/min/1.73 m2/y)
for each patient was calculated using linear regression
with varying intercepts and varying slopes, but without
covariates, for the estimation of annual changes in eGFR.
Other cut-off values were also applied in sensitivity tests.
To compare the performances of a new predictive
model versus an old predictive model, the integrated dis-
crimination improvement (IDI) was applied, which calcu-
lates integrated sensitivity (IS) and integrated one minus
specificity (IP) in the old and new models as IDI = (ISnew -
ISold) - (IPnew - IPold) [18].
Statistical analysis
The baseline characteristics of all patients are expressed
as percentages for categorical data, in mean ± standard
Table 1 Baseline characteristic of CKD stages 3–4 patients according to quartiles of serum calcium level
Quartile of serum calcium level (mg/dL)
Q1 Q2 Q3 Q4
All patients (<9.0) (9.0 - 9.4) (9.4 - 9.8) (>9.8) p for trend
No. of patients 2144 544 452 588 560 -
Demographic data
Age, yrs 64.2 ± 13.5 64.1 ± 14.3 64.8 ± 13.7 63.8 ± 13.2 64.1 ± 13.0 0.636
Gender (female) 756 (35.3%) 179 (32.9%) 149 (33.0%) 207 (35.2%) 221 (39.5%) 0.017
Diabetes mellitus 940 (43.8%) 209 (38.4%) 184 (40.7%) 265 (45.1%) 282 (50.4%) <0.001
Cardiovascular disease 381 (17.8%) 101 (18.6%) 92 (20.4%) 94 (16.0%) 94 (16.8%) 0.197
Hypertension 1360 (63.4%) 386 (71.0%) 303 (67.0%) 364 (61.9%) 307 (54.8%) <0.001
Smoker (recent) 279 (13.0%) 70 (12.9%) 56 (12.4%) 78 (13.3%) 75 (13.4%) 0.711
Mean BP, mmHg 99.4 ± 13.5 97.9 ± 13.1 99.1 ± 12.9 100.5 ± 14.8 100.1 ± 12.7 0.002
Body mass index, kg/m2 25.0 ± 3.9 24.6 ± 3.8 25.2 ± 3.8 25.1 ± 4.1 25.3 ± 4.1 0.017
Laboratory results
eGFR, ml/min/1.73 m2 33.2 ± 11.9 31.2 ± 11.8 33.4 ± 11.8 34.5 ± 11.8 33.5 ± 11.9 0.001
Hemoglobin, g/dL 11.9 ± 2.1 11.5 ± 2.0 12.1 ± 2.1 12.1 ± 2.1 12.0 ± 2.1 <0.001
Albumin, g/dL 3.9 ± 0.5 3.9 ± 0.4 3.9 ± 0.4 3.9 ± 0.5 3.8 ± 0.6 0.003
GPT, U/I 26.3 ± 25.1 24.4 ± 23.8 25.5 ± 24.6 27.1 ± 27.4 28.2 ± 24.0 0.006
Cholesterol, mg/dL 192.0 (165.0-223.5) 187.0 (160.0-213.0) 190.0 (163.0-217.8) 194.0 (168.8-224.0) 198.0 (167.6-232.8) <0.001
Triglyceride, mg/dL 127.0 (93.0-189.0) 117.0 (86.3-171.7) 123.0 (89.0-172.8) 134.0 (97.0-188.0) 141.0 (100.0-212.8) <0.001
WBC, x103/uL 7.2 ± 2.3 7.1 ± 2.4 7.1 ± 2.1 7.1 ± 2.1 7.5 ± 2.4 0.012
CRP, mg/dL; 1.0 (0.3-4.6) 1.1 (0.5-4.0) 1.0 (0.4-3.3) 0.9 (0.3-4.2) 1.2 (0.2-7.3) 0.993
HbA1c, mg/dL; 6.6 ± 1.7 6.4 ± 1.5 6.3 ± 1.4 6.7 ± 1.7 7.0 ± 1.8 <0.001
UPCR, mg/g 702.8 (263.0-1697.7) 800.7 (334.6-1778.8) 721.3 (269.9-1670.1) 615.6 (229.1-1698.2) 659.8 (244.9 - 1698.6) 0.016
Sodium, mEq/L 138.6 ± 3.4 138.2 ± 3.4 138.7 ± 3.1 138.9 ± 3.4 138.8 ± 3.6 0.003
Potassium, mEq/L 4.3 ± 0.5 4.3 ± 0.5 4.2 ± 0.5 4.3 ± 0.5 4.4 ± 0.5 <0.001
Phosphorus, mg/dL 3.9 ± 0.8 4.0 ± 0.9 3.9 ± 0.8 3.9 ± 0.8 3.9 ± 0.7 0.019
Calcium, mg/dL 9.2 ± 0.7 8.6 ± 0.5 9.1 ± 0.3 9.3 ± 0.3 10.0 ± 0.5 <0.001
Ca x Pi 36.2 ± 7.5 34.2 ± 7.4 35.1 ± 7.0 36.6 ± 7.5 38.5 ± 7.2 <0.001
PTH, pg/mL 68.4 ± 79.5 96.2 ± 105.8 66.3 ± 68.6 61.6 ± 72.2 50.4 ± 54.4 <0.001
Bicarbonate, mEq/L 23.4 ± 3.6 22.6 ± 3.8 23.6 ± 3.5 23.8 ± 3.5 23.8 ± 3.7 <0.001
Uric acid, mg/dL 7.8 ± 1.9 7.8 ± 1.9 7.7 ± 1.9 7.7 ± 1.8 7.8 ± 2.0 0.588
Phosphate binder 381 (17.8%) 105 (19.3%) 86 (19.0%) 92 (15.6%) 98 (17.5%) 0.129
Outcome
Follow-up, days 1085(682–1673) 1061 (673–1608) 1059 (676–1575) 1092 (688–1686) 1191 (705–1749) 0.017
LVMI 118.5 (45.0) 129.2 (42.9) 121.9 (56.3) 112.3 (42.7) 114.1 (37.6) 0.037
eGFR slope, ml/min/
1.73 m2/yr
−1.9 (−5.4-0.5) −2.6 (−6.2-0.1) −1.7 (−4.7-0.5) −1.9 (−5.6-0.5) −1.4 (−4.9-1.1) <0.001
Rapid renal progression 574 (27.0%) 172 (31.9%) 115 (25.4%) 151 (25.7%) 136 (24.5%) 0.029
RRT 294 (13.7%) 107 (19.7%) 54 (11.9%) 73 (12.4%) 60 (10.7%) <0.001
Death 270 (12.6%) 56 (10.3%) 53 (11.7%) 65 (11.1%) 96 (17.1%) <0.001
CKD, Chronic kidney disease; BP, Blood pressure; eGFR, Estimated glomerular filtration rate; GPT, Glutamic pyruvic transaminase; WBC, White blood cell count; CRP,
C-reactive protein; HbA1c, Glycosylated hemoglobin; UPCR, Urine protein to creatinine ratio; Ca x Pi, Calcium phosphate product; PTH, Parathyroid hormone; RRT,
Renal Replacement Therapy; LVMI, Left ventricular mass index; LVH, Left ventricular hypertrophy.
Continuous variables are expressed as mean ± standard deviation or median (interquartile range), and categorical variables are expressed as number (percentage).
P for trend <0.05 indicates a significant trend for increasing calcium levels.
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Table 2 Multivariate linear regression for serum calcium
in CKD stage 3–4 patients
Variables β coefficient 95% CI p-value
Age, yrs −0.001 −0.003 to 0.001 0.370
Gender (male vs. female) 0.143 0.084 to 0.202 <0.001
Diabetes mellitus 0.088 0.030 to 0.147 0.003
Cardiovascular disease −0.102 −0.163 to −0.041 0.001
Mean BP, mmHg 0.001 −0.001 to 0.003 0.145
Body mass index, kg/m2 0.002 −0.005 to 0.009 0.562
eGFR, ml/min/1.73 m2 −0.004 −0.006 to −0.001 0.010
Hemoglobin, g/dL 0.025 0.009 to 0.041 0.003
Albumin, g/dL −0.211 −0.270 to −0.151 <0.001
Log (Cholesterol) 0.467 0.222 to 0.711 <0.001
Ln (CRP) 0.010 −0.020 to 0.040 0.504
HbA1c,mg/dL; 0.036 0.019 to 0.054 <0.001
Log (UPCR) −0.110 −0.168 to −0.052 <0.001
Phosphorus, mg/dL −0.062 −0.097 to −0.027 <0.001
PTH, pg/mL −0.002 −0.002 to −0.002 <0.001
Phosphate binder −0.031 −0.105 to 0.044 0.419
CKD, Chronic kidney disease; BP, Blood pressure; eGFR, Estimated glomerular
filtration rate; CRP, C-reactive protein; HbA1c, Glycosylated hemoglobin; UPCR,
Urine protein to creatinine ratio; PTH, parathyroid hormone.
P <0.05 indicates a significant associated with serum calcium levels.
Table 3 Association of calcium with renal replacement therap
Quarti
Q1 Q
HR (95% CI) (<9.0) (9.0
Renal replacement therapy
Unadjusted 2.12 (1.55-2.91)* 1.26 (0.
Model 1 1.52 (1.10-2.10)* 1.32 (0.
Model 2 1.64 (1.19-2.26)* 1.32 (0.
Model 3 2.34 (1.65-3.31)* 1.58 (1.1
Model 4 2.12 (1.49-3.02)* 1.50 (1.0
Rapid renal function progression
Unadjusted 1.44 (1.11-1.88)* 1.18 (0.
Model 1 1.42 (1.06-1.91)* 1.28 (0.
Model 2 1.56 (1.15-2.10)* 1.30 (0.
Model 3 1.72 (1.25-2.35)* 1.40 (1.0
Model 4 1.65 (1.19-2.27)* 1.35 (0.
Model 1 adjusts for age, gender, eGFR, log(UPCR).
Model 2 adjusts for covariates in model 1 plus diabetes mellitus, cardio vascular dis
Model 3 adjusts for covariates in model 2 plus hemoglobin, albumin, log(cholestero
Model 4 adjusts for covariates in model 3 plus phosphorus, phosphate binder, PTH.
HR, Hazard ratio; eGFR, Estimated glomerular filtration rate; UPCR, Urine protein to c
Parathyroid hormone.
*(p <0.05) indicates a significantly different from reference group.
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http://www.biomedcentral.com/1471-2369/15/183deviation (SD) for continuous variables with approxi-
mately normal distribution, and median and interquartile
ranges for continuous variables with skewed distribution.
Cox proportional hazards analyses were used to evalu-
ate the hazard ratios (HR) for RRT associated with cal-
cium levels. Multivariate logistic regression analyses
were used to evaluate the association between calcium
and rapid renal disease progression. Covariates were in-
cluded into these models if the P value was <0.05 in uni-
variate analysis and skewed distributed continuous
variables were log-transformed to attain normal distribu-
tion. The adjusted covariates included age, sex, eGFR,
urine protein to creatinine (UPCR) ratio log, CVD, DM,
glycosylated hemoglobin, mean blood pressure (MBP),
hemoglobin, albumin, C-reactive protein, body mass
index (BMI), cholesterol log, phosphorus, use of phos-
phate binders, and iPTH. A P value <0.05 was consid-
ered statistically significant. Statistical analysis was
performed using the R 2.15.2 software (R Foundation for
Statistical Computing, Vienna, Austria) and the Statis-
tical Package for Social Sciences version 18.0 for Win-
dows (SPSS Inc, Chicago, IL, USA).
Results
Baseline characteristics of the study group according to
calcium quartiles
Table 1 displays the baseline characteristics of the study pa-
tients. The mean calcium level was 9.2 ± 0.7 mg/dL. The
mean eGFR was 33.2 ± 11.9 mL/min/1.73 m2. The patientsy and rapid renal function progression
le of serum calcium level (mg/dL)
2 Q3 Q4
- 9.4) (9.4 - 9.8) (>9.8)
90-1.76) 1.15 (0.79-1.68) 1 (reference)
94-1.86) 0.97 (0.67-1.42) 1 (reference)
94-1.86) 1.05 (0.72-1.54) 1 (reference)
1-2.25)* 1.51 (1.01-2.25)* 1 (reference)
5-2.15)* 1.42 (0.95-2.12) 1 (reference)
90-1.54) 0.94 (0.70-1.26) 1 (reference)
95-1.71) 0.93 (0.67-1.28) 1 (reference)
97-1.75) 0.98 (0.71-1.36) 1 (reference)
3-1.91)* 1.15 (0.82-1.61) 1 (reference)
99-1.84) 1.11 (0.79-1.56) 1 (reference)
ease, HbA1c, mean BP.
l), ln(CRP), body mass index.
reatinine ratio; HbA1c, Glycosylated hemoglobin; BP, Blood pressure; PTH,
Figure 1 Renal survival curves according to calcium and
phosphorus level. a Risk for renal replacement therapy (RRT)
according to serum calcium. b Mineral disorder and risk for renal
replacement therapy (RRT).
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http://www.biomedcentral.com/1471-2369/15/183from the Ca Q1 subgroup were more likely to have lower
MBP, lower eGFR, hemoglobin, and bicarbonate levels, and
higher UPCR and iPTH levels than were the other calcium
quartile groups. The use of phosphate binders showed
non-significant differences between the groups.
Table 2 shows the variables associated with serum cal-
cium in CKD stages 3–4. Female sex, DM, hemoglobin,
HbA1c and cholesterol log levels showed positive corre-
lations with serum calcium. In contrast, CVD, eGFR, al-
bumin, phosphorus, iPTH, and UPCR log levels showed
negative correlations with serum calcium.
Calcium and left ventricular hypertrophy
Table 1 shows the echocardiography findings according
to quartiles of serum calcium. Patients with serum cal-
cium <9.0 mg/dL have higher LVMI compared with others
quartiles, which were 129.2 g/m2 (P < 0.05) and 42.9% re-
spectively. Lower serum calcium demonstrated an in-
creased risk of LVH with an adjusted OR of 1.64 (95%
CI = 0.98–2.95, P < 0.05) (Additional file 1: Table S1).
Calcium and RRT
During a median 2.9-year follow-up period, there were
total of 294 patients (13.7%) commencing RRT (Table 1).
The percentage of patients requiring RRT was highest in
the Ca Q1 group (19.7%) compared other groups. Lower
serum calcium was associated with increased risk of re-
quiring RRT, with an adjusted HR of 2.12 (95% CI = 1.49–
3.02, P <0.05) when comparing the Ca Q1 and Ca Q4
groups (Table 3). Figure 1a shows the renal survival curves
for the calcium quartile groups. We also performed a sur-
vival analysis for RRT in the pre-specified subgroups.
Non-significant interactions were observed (Figure 2).
Calcium and rapid renal function progression
The median eGFR slope was −1.9 mL/min/1.73 m2/y.
The Ca Q1 group was associated with the greatest renal
functional decline, with an eGFR slope of −2.6 mL/min/
1.73 m2/y compared with −1.4 mL/min/1.73 m2/y in
the Ca Q4 group. Table 3 also lists the odds ratios for
rapid renal function progression, defined as an eGFR
slope < −5 mL/min/1.73 m2/y. Lower serum calcium was
associated with increased risk of rapid renal function pro-
gression, with an adjusted OR of 1.65 (95% CI = 1.19–2.27)
when comparing the Ca Q1 and Ca Q4 groups (Table 3).
However, higher serum calcium showed no association with
increased risk of rapid renal function progression when
comparing the Ca Q4 and Ca Q3 groups.
Serum calcium and phosphorus are predictive of
requiring RRT
To evaluate the combined effects of serum calcium and
phosphorus on the requirement for RRT, we further divided
the patients into calcium (≥9.1 mg/dL and <9.1 mg/dL) andphosphorus (≥4.2 mg/dL and <4.2 mg/dL) subgroups. The
group with lower serum calcium (<9.1 mg/dL) and higher
phosphorus (>4.2 mg/dL) was associated with increased
risk of requiring RRT, with an adjusted HR of 2.31 (95%
CI = 1.45–3.67, P <0.05) (Table 4). Figure 1b shows the
renal survival curves according to calcium and phosphorus
levels. When serum calcium was added into the survival
model, the IDI increased, with a discrimination slope 0.08%
higher than the original (Model 3 vs Model 1, IDI 0.80%
(0.12% – 1.91%); Table 5). Conversely, Ca × P was add into
the survival model, the discrimination slope was 0.05%
lower than the original (Model 4 vs Model 1, IDI −0.50%
(−0.94% –0.07%); Table 5).
Discussion
In this study, we showed that low serum calcium
(<9.0 mg/dL) is an independent prognostic marker of re-
quiring RRT and rapid renal function progression in
CKD stages 3–4 patients. We did not observe any asso-
ciation between high serum calcium (>9.8 mg/dL) and
renal outcome.
Figure 2 Adjusted hazard ratio of renal replacement therapy (RRT) for 1 mg/dL decreased of serum calcium in different subgroup.
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http://www.biomedcentral.com/1471-2369/15/183Previous epidemiological studies on CKD patients have
focused on the association between bone mineral dis-
order and outcomes [4,7,19,20]. Although these studies
have extensively investigated several of the abnormalities
that characterize CKD mineral and bone disorder (CKD-
MBD), such as serum phosphorus, iPTH, vitamin D, and
FGF-23, and their roles as biomarkers for prediction of
outcomes in a CKD population, few studies have evalu-
ated serum calcium and renal outcome in CKD. Re-
cently, Lundberg et al. identified that reduced serum
calcium (per 0.1 mmol/L) was associated with higher
time-averaged albuminuria, and predictive of deterior-
ation in renal function, in an observational cohort
of IgA nephropathy patients [21]. Our study resultsTable 4 Mineral disorder and risk of renal outcomes
Hazard ratio (95% C
replacement t
P > 4.2 mg/dl Ca > 9.1 mg/dl Unadjusted
No Yes 1 (reference)
No No 1.58 (0.94-2.66)
Yes Yes 4.76 (3.01-7.53)*
Yes No 6.64 (4.28-10.32)*
Adjusts the variables including age, gender, eGFR, log(UPCR), diabetes mellitus, card
(CRP), body mass index, phosphate binder and PTH.
eGFR, Estimated glomerular filtration rate; UPCR, Urine protein to creatinine ratio; Hb
*(p <0.05) indicates a significantly different from reference group.suggested that serum calcium should be included in
models for the estimation of the risk of renal events.
Serum calcium is a commonly collected laboratory par-
ameter in most institutions. However, vitamin D and
FGF-23 levels are not typically day-to-day clinical mea-
surements. Therefore, serum calcium provides a more
convenient parameter as a clinical predictor of kidney dis-
ease progression.
Several potential mechanisms could explain our study
observations. First, hypocalcemia, hyperparathyroidism,
and vitamin D deficiency could be associated with in-
creased circulating FGF-23 levels and renal functional de-
terioration. Studies have shown an inverse association
between renal function and FGF-23 levels in CKD [20,22].I) for renal
herapy
Odd ratio (95% CI) for rapid renal
function progression
Adjusted Unadjusted Adjusted
1 (reference) 1 (reference) 1 (reference)
1.21 (0.71-2.07) 1.15 (0.85-1.57) 1.07 (0.76-1.51)
1.53 (0.94-2.47) 2.37 (1.76-3.20)* 1.26 (0.88-1.79)
2.31 (1.45-3.67)* 2.70 (2.02-3.59)* 1.68 (1.20-2.35)*
io vascular disease, HbA1c, mean BP, hemoglobin, albumin, log(cholesterol), ln
A1c, Glycosylated hemoglobin; BP, Blood pressure; PTH, Parathyroid hormone.
Table 5 Integrated discrimination improvement (IDI) of
adding phosphorus, calcium or calcium x phosphorus in
the survival model
IDI % (95% CI)
vs. Model 0 vs. Model 1
Model 0 - -
Model 1 (Model 0 + Pi) 0.74 (0.06 – 1.53)* -
Model 2 (Model 0 + Ca) 0.82 (0.00 – 1.98)* 0.07 (−0.97 – 2.46)
Model 3 (Model 0 + Pi + Ca) 1.55 (0.16 – 2.90)* 0.80 (0.12 – 1.91)*
Model 4 (Model 0 + Ca x Pi) 0.23 (−0.16 – 0.80) −0.50 (−0.94 – 0.07)
Model 0 included the following variables: age, gender, eGFR, log(UPCR),
diabetes mellitus, cardio vascular disease, HbA1c, mean BP, hemoglobin,
albumin, log(cholesterol), ln(CRP), body mass index, phosphate binder
and PTH.
eGFR, Estimated glomerular filtration rate; UPCR, Urine protein to creatinine
ratio; HbA1c, Glycosylated hemoglobin; BP, Blood pressure; PTH,
Parathyroid hormone.
*P < 0.05.
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http://www.biomedcentral.com/1471-2369/15/183Isakova et al. evaluated a large prospective cohort of pa-
tients with CKD stages 2–4, and identified that elevated
FGF-23 is an independent risk factor for end-stage renal
disease (ESRD) [23]. Nakano et al. further reported that
increased FGF-23 was significantly associated with higher
risk of ESRD, irrespective of CKD stage, and that serum
calcium was associated with renal events after adjusting
for FGF-23 [24].
In an advanced CKD population, suboptimal levels of
1,25(OH)2D3 are frequently observed. Experimental and
epidemiologic data have emphasized the contribution of
a deficiency in vitamin D toward impaired kidney func-
tion [25,26]. Low plasma 1,25(OH)2)D increases the
likelihood of requiring long-term dialysis in patients
with advanced CKD [8]. De Boer et al. observed a low
serum 25-hydroxyvitamin D concentration (25(OH)D)
and rapid reduction in GFR in older adults with normal
baseline kidney function [27]. Therefore, hypocalcemia
might indicate the severity of vitamin D deficiency and
emphasize its pathophysiological role in renal functional
decline.
During early CKD, iPTH levels are typically elevated
and might contribute to various complications [28].
Hypocalcemia in CKD can be associated with secondary
hyperparathyroidism (SHPT). Previous studies have
shown that higher mortality was associated with SHPT
in maintenance hemodialysis patients [29,30] and in a
cohort of men with CKD stages 3–5 [31]. The associ-
ation between SHPT and renal function progression is
not well-characterized. In a nephrectomized animal
model, iPTH accelerated CKD progression in rats with a
high-protein diet [32]. In a small cohort of diabetic pre-
dialysis patients, SHPT was associated with a higher rate
of CKD progression [33]. In our cohort, low serum cal-
cium remains significantly associated with RRT andrapid renal function progression after adjustment for co-
variates (Table 3).
Calcium ion is responsible for the nerve and synaptic
excitation as well as cardiac myocytes contraction [34].
The effect of hypocalcemia on myocardial cells is un-
clear, but we know that the excitation-contraction coup-
ling of the heart depends on the flow of ionized calcium
[35]. In the complicated metabolic environment of CKD
patients, the direct effect of serum calcium on cardiac
performance remained controversial. In CKD patients,
Gromadzinski L et al. have shown that hypocalcemia is
related to left ventricular diastolic dysfunction [34]. In
our study, low serum calcium was associated with lower
MAP and higher percentage of LVMI (Table 1). There-
fore, this association might have contributed to rapid
renal function progression and the requirement for RRT.
Investigators have proposed that calcium overload
plays a direct role in the pathogenesis of acute kidney in-
jury by altering cellular function [11]. In a population of
hemodialysis patients, Tentori et al. observed that serum
calcium >10 mg/dL was associated with the highest risk
of mortality [36]. However, in our study, high serum cal-
cium (>9.8 mg/dL) did not show an association with
lower eGFR at baseline or with poor renal outcomes at
follow-up [2,37]. These results could be attributed to
fewer hypercalcemic patients, and low usage of calcium-
containing phosphate binders, in our cohort.
Numerous epidemiological studies have shown a cor-
relation between Ca × P and cardiovascular outcome and
mortality [3,38,39]. The role of Ca × P in CKD progres-
sion remains controversial. Schwarz et al. showed that
higher Ca × P was associated with higher risk of progres-
sive CKD [2]. However, the role of Ca × P as an inde-
pendent risk factor for morbidity and mortality is
questionable because serum phosphorus, which is well-
known as a novel risk factor for kidney disease progres-
sion and mortality in CKD, could have predominantly
contributed to the variability in the parameter [4,40].
Tentori F et al. in The Dialysis Outcomes and Practice
Patterns Study (DOPPS) demonstrated that the combin-
ation of high calcium and high phosphorus accounted
for the greatest risk of mortality in dialysis patients [36].
In Our study, patients with high serum phosphorus
(>4.2 mg/dL) in combination with low serum calcium
(<9.1 mg/dL) were associated with the highest risk of
kidney disease progression. Our results suggested that the
combination of serum phosphorus and calcium may pro-
vide a more accurate clinical marker than serum phos-
phorus or calcium alone does. Whether calcium should be
regarded as a risk factor in the risk model would need fur-
ther study to verify.
Our study has several limitations. First, it is a cohort
study and not a randomized controlled trial. Therefore,
our results showed only the association between serum
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http://www.biomedcentral.com/1471-2369/15/183calcium and renal outcome. In our cohort, patient with
low serum calcium have low GFR and more rapid decline
in renal function. However, there are many precipitated co-
morbidities which contribute to poor GFR. Further investi-
gation is required to identify the mechanism(s) underlying
serum calcium and kidney disease progression. Second,
our study cohort was an advanced CKD population. There-
fore, our study results might not be applicable in earlier
stage CKD patients. Third, we did not measure vitamin D
and FGF-23 levels. In our patients, the use of vitamin D
and calcium-containing phosphate binders was relatively
low. Therefore, we were unable to identify the effects of
these compounds. Fourth, cardiac echography examin-
ation is only applicable to patients who entered CKD stage
5. However, previous studies that evaluated vitamin D and
FGF-23 have shown the prognostic value of calcium in
renal disease. Fifth, ionized calcium was not measured in
our study. Further larger investigations should be con-
ducted to confirm these results.
Conclusion
In conclusion, our study results show that low serum
calcium is associated with increased risk of requiring
RRT and rapid renal function progression. The integra-
tion of serum calcium and phosphorus, but not calcium-
phosphorus product should be considered in a predictive
model of renal outcome.
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